Quinoxalines are common structural motifs found in a variety of biologically active compounds for anti-cancer, anti-inflammatory, antimalarial, anti-HIV and antimicrobial indications. Janssen Oncology received approval from FDA for use of Balversa as a first targeted therapy for metastatic blood cancer in April, 2019. Patients with locally advanced or metastatic urothelial carcinoma that has susceptible Fibroblast growth factor receptor 2 (FGFR2) or FGFR3 genetic alterations and that has progressed during or following prior platinum-containing chemotherapy were treated with this regimen. The efficacy studies of Balversa were conducted on selected 87 patients based on above criteria and results are promising with 2.3% patients having complete response and 30% showing partial response to the treatment.
With more customised drugs becoming the standard to target various disease type based on patient’s specific biomarkers or genetic mutation ChemAladdin offers broad range of building blocks to enable the construction of interesting new molecules. Below we are showcasing selected examples of quinoxaline derivatives in context of our highlighted molecule. For more, please visit https://www.chemaladdin.com/ to register and search from millions of building blocks, screening compounds and reaction intermediates.
 Tariq S.; Somakala, K.; Amir, M. Eur. J. Med. Chem. 2018, 143, 542–557